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Abstract Glaucoma is a major cause of vision loss
worldwide with nearly 8 million people bilaterally blind
from the disease. This number is estimated to increase over
the next 10 years. The key to preventing blindness from
glaucoma is effective diagnosis and treatment. The classical
glaucoma treatment focuses on intraocular pressure (IOP)
reduction. Better knowledge of the pathogenesis has
opened up additional therapeutical approaches often called
non-IOP lowering treatment. Whilst most of these new
avenues of treatment are still in the experimental phase,
others are already used by some physicians. These new
therapeutic approaches allow a more personalised patient
treatment. Non-IOP lowering treatment includes improve-
ments of ocular blood flow, particularly blood flow
regulation. This can be achieved by improving the
regulation of ocular blood flow (improving autoregulation)
by drugs such as carbonic anhydrase inhibitors, magnesium
or calcium channel blockers. It can also be improved by
decreasing blood pressure over-dips. Blood pressure can be
increased by an increase in salt intake or in rare cases by
treatment with fludrocortisone. Experimentally, glaucoma-
tous optic neuropathy can be prevented by inhibition of
astrocyte activation, either by blockage of epidermal
growth factor receptor or by counteracting Endothelin.
Glaucomatous optic neuropathy can also be prevented by
nitric oxide-2 synthase inhibition. Suppression of matrix
metalloproteinase-9 inhibits apoptosis of retinal ganglion
cells and tissue remodelling. Upregulation of heat shock
proteins protects the retinal ganglion cells and the optic nerve
head. Reduction of oxidative stress especially at the level of
mitochondria also seems to be protective. This can be
achieved by gingko, dark chocolate, polyphenolic flavonoids
occurring in tea, coffee or red wine and anthocyanosides
found in bilberries as well as by ubiquinone and melatonin.
This review describes the individual mechanisms which may
be targeted by non-IOP lowering treatment based on our
pathogenic scheme.
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Introduction
For the past century glaucoma has been considered a
disease for which diagnosis and treatment was focussed
mainly on intraocular pressure. Large studies such as ‘The
Ocular Hypertension Treatment Study’ or ‘The European
Glaucoma Prevention Study’ recognised ocular hyperten-
sion as the most important factor for the development of
primary open angle glaucoma. Because elevated intraocular
pressure (IOP) was associated with the development of
glaucoma, and reducing IOP, reduced the risk of visual field
progression, IOP was considered a good surrogate for
glaucoma treatment. The focus on IOP as the only risk
factor, however, left several questions unanswered: Why do
the majority of people with increased IOP not develop
glaucomatous optic neuropathy (GON) (Fig. 1)? On the
other hand, why do we see an increasing number of patients
acquiring GON who have an IOP in the normal range?
Why does reduction of IOP, whilst on the average
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improving prognosis, not stop progression in all patients?
And why do some patients need a very low IOP, indeed
sometimes an even unphysiological low IOP to stop progres-
sion of this disease? These questions can be answered when
considering additional risk factors such as systemic hypoten-
sion or vascular dysregulation. The elucidation of these
additional factors has lead to the investigation of non-IOP
lowering treatment. Whether such treatment will be an
adjunctive to the conventional IOP-lowering treatment (e.g.
in patients with primary open angle glaucoma (POAG)) or
whether it shall be used by itself (e.g. in patients with normal-
tension glaucoma (NTG)) remains to be seen.
Some IOP lowering glaucoma medications have additional
effects. For example carbonic anhydrase inhibitors improve
regulation of ocular perfusion. This review, however, will
focus solely on drugs that do not reduce IOP. Furthermore, we
will discuss prevention of GON and only marginally deal
with the prevention of IOP increase.
For more details on the pathogenesis and risk factors in
glaucoma we refer to the article by Flammer and Mozaffarieh
[1]. Fact remains that glaucoma is a multifactorial disease
in which the different risk factors known may finally
damage through the same or similar pathomechanisms. In
order to visualise the individual mechanisms that may be
targeted by treatment we have recapitulated the figure of the
pathogenic scheme by Flammer and Mozaffarieh (Fig. 2)
[1]. The section numbers below correspond to the numbers
in Fig. 1.
Therapeutic targets
1. Inhibition of epidermal growth factor receptor (EGFR)
prevents the activation of astrocytes and improves
ocular blood flow
1A. Combat of mechanical stress prevents the activation
of astrocytes
The activation of the astrocytes in the optic nerve head
(ONH) and retina plays an essential role in the pathogenesis
of GON [2–4]. Both mechanical and ischemic stress can
Fig. 1 Normal optic disc. a Normal optic disc in a healthy person (left), in the eye of a cadaver (middle), and a histological section (right). b
Glaucomatous atrophy of the optic disc. The eye of the patient is shown on the left, of a cadaver in the middle and a histological section in the right
Fig. 2 The pathogenetic scheme of GON. The pathogenetic scheme
by Flammer and Mozaffarieh [1], depicts the individual mechanisms
that may be targeted by non-IOP lowering treatment. The numbers in
red correspond to the section numbers in the manuscript
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lead to activation of astrocytes. Once activated astrocytes
upregulate the production of various molecules, including
matrix metalloproteinases (MMP’s), nitric oxide synthase-2
(NOS-2), tumor necrosis factor- alpha (TNF- α), and
Endothelin, thereby creating an altered microenvironment
leading to tissue remodelling and axonal damage. Mechan-
ical stress leads to stimulation of EGFR which, in turn,
leads to activation of astrocytes and thereby to an
upregulation of NOS-2. Blockage of EGFR, by a tyrosine
kinase inhibitor therefore prevents the activation of astro-
cytes [5]. Interestingly, such a treatment not only inhibits
the activation of astrocytes but also leads to a reduction of
loss of retinal ganglion cells. This indirectly indicates that
the activation of astrocytes is relevant in GON [2, 3, 6].
Whether this approach will lead to glaucoma treatment in
humans can at the moment not be predicted.
1B. Inhibition of the effect of Endothelin-1 improves
ocular blood flow
In glaucoma patients plasma concentration of Endothelin-1
(EN-1) is increased [7]. Endothelin not only further reduces
optic nerve head blood flow and impairs anterograde and
retrograde axoplasmatic transport [8, 9], but also activates
astrocytes [10]. This is further supported by the fact that
patients with a vascular dysregulation more often have
activated retinal astrocytes which can be visualised clini-
cally [11, 12]. The effect of Endothelin can be partially
blocked by a number of different drugs such as calcium
channel blockers (CCB’s) including magnesium (a physio-
logical CCB (Fig. 3)), dipyrimadole or Endothelin blockers
[13–16]. Whether an inhibition of Endothelin indeed also
inhibits the activation of astrocytes has not yet been
studied.
2. Inhibition of nitric oxide synthase 2 (NOS-2) decreases
damage
Nitric oxide (NO), also known as the “endothelium-derived
relaxing factor”, is biosynthesised from arginine and
oxygen by various nitric oxide synthase (NOS) enzymes.
There are three basic forms of NOS: Neuronal nitric oxide
synthase (nNOS or NOS-1), inducible nitric oxide synthase
(iNOS or NOS-2) and endothelial nitric oxide synthase
(eNOS or NOS-3).
Nitric oxide synthase -2 (NOS-2), leads to a marked
production of nitric oxide. NOS-2 can be inhibited by the
drug aminoguanidine, a nucleophilic hydrazine compound.
Aminoguanidine is an oral insulin stimulant for type 2
diabetes mellitus. It further seems to prevent the formation
of advanced glycation end products [17]. In addition, it is a
relative specific inhibitor of NOS-2 which is why it was
studied in experimental glaucoma. In experimental glauco-
ma aminoguanidine was capable of preventing the devel-
opment of GON [18]. Such treatment appears very
promising but clinical studies are not yet available.
3. Reduction of severe hypotension improves prognosis
Low blood pressure as well as nocturnal over dipping
increases the probability of visual field deterioration [19,
20]. We can therefore assume that an increase in blood
pressure in patients with hypotension may improve prog-
nosis although interventional studies supporting this view
are rare. Treatment of hypotension with vasoconstrictive
drugs although increasing blood pressure may further
reduce blood flow. Blood pressure, however, can be
increased with an increase in salt intake (1–5 g daily)
[21]. In severe cases the intake of the low–dosed fludro-
cortisone, (0.1 mg/2x per week) has been described [22].
Fludrocortisone treatment not only slightly increases blood
pressure and reduces nocturnal dips but also improves the
regulation of blood flow indirectly [22].
4. Improvement of vascular regulation (autoregulation)
stabilises oxygen supply
Vascular dysregulation is a major risk factor for GON [23].
Vascular regulation can be improved by various drugs.
Among the IOP lowering drugs, only carbonic anhydrase
inhibitors (in particular dorzolamide), have proven to both
increase ocular blood flow (OBF) and improve the
regulation of OBF [24], thereby decreasing the chance of
reperfusion injury [25].
Fig. 3 Magnesium inhibits the effect of endothelin-1 (ET-1). Relaxing
effect of increasing concentrations of MgSO4 and MgCl2 added to
endothelial-precontracted porcine ciliary arteries (−10−8M). NaCl,
which has the same osmolarity as MgSO4, did not evoke a relaxation
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Parallel to an improvement in OBF, an improvement in
visual field was observed (Fig. 4). Carbonic anhydrase
inhibitors (CAI), like acetazolamide, improve visual fields
in glaucoma patients [26–28]. Similar effects have been
observed for calcium channel blockers (CCB’s). An improve-
ment in OBF and visual function was only observed in
patients with a vascular dysregulation [29]. Accordingly, a
positive response to OBF on carbon-dioxide breathing
predicts the effect of CCB’s on OBF [30]. The effect of
CCB’s on visual field have also been demonstrated in masked
double blind studies [31]. Likewise, CCB’s decreased the
OBF reducing effect of an Endothelin infusion in healthy
volunteers [32]. Dipyridamol, a drug often used in the past as
a platelet inhibitor, also inhibits the effect of Endothelin [33],
and improves OBF [34]. Unfortunately the long-term role of
dipyrimadole on glaucoma patients has not yet been studied.
Among the systemic treatments, magnesium is a weak but
harmless drug that inhibits the effect of Endothelin partially
[13] and improves OBF [15].
Omega-3-fatty acids (Omega 3-FA’s) have a number of
different effects including the modulation of intracellular
calcium ion release and thereby the stabilisation of
circulation [35]. Omega 3-FA’s also increase the production
of uncoupling proteins and thereby improve ATP indepen-
dent heat production which is most probably impaired in
patients with vascular dysregulation [36, 37].
Cacao beans from the seed of Theobroma Cacao contain a
subclass of flavonoids, flavan-3-ols, which have been reported
to augment endothelial nitric oxide synthase (eNOS), and
thereby nitric oxide (NO). This improves endothelium
dependent vasorelaxation [38]. Unfortunately the use of cacoa
beans has not yet been studied in the context of glaucoma.
5. Reduction of oxidative stress improves prognosis
Free radicals are involved in a number of inflammatory and
degenerative diseases. Accordingly, oxidative stress is
involved in the pathogenesis of GON where free radicals
cause a damage to retinal ganglion cells and their axons
[39, 40]. In addition, oxidative stress leads to degeneration
of trabecular meshwork (TM) [41, 42] and thereby
alterations in the aqueous outflow pathway (Fig. 5), leading
to increased IOP which, in turn, also damages retinal
ganglion cells. The target of oxidative stress relevant in the
development of GON are most probably the mitochondria
[43]. It is therefore desirable to have a drug protecting the
mitochondria, in particular the mitochondria of the optic
nerve head [43]. This can unfortunately not be achieved by
an increase intake of vitamins such as vitamin C or vitamin E.
Only molecules reaching the inner membrane of the mito-
chondria can be of potential use. Ginkgo contains a number of
substances, including polyphenolic flavonoids, that have been
proven to protect the mitochondria from oxidative stress and
thereby protect the retinal ganglion cells [44–47]. Moreover,
ginkgo has been shown to improve visual fields in a long
term double masked placebo-controlled study [48]. Efficacy
and safety reports have suggested a daily dose of 120 mg to
be sufficient and acceptable [49].
There are a number of other naturally occurring
substances that could theoretically be beneficial but have
not been studied for glaucoma [50–52]. Polyphenolic
flavonoids have strong antioxidant capacity due to their
free radical scavenging properties. Both green and black
tea, are rich sources of flavonoids such as catechin (C),
epicatechin (EC), epigallocatechin (EGC) [53, 54]. Coffee
also has good antioxidant properties due to polyphenolic
compounds. In addition, coffee contains the molecule 3-
methyl-1,2-cyclopentanedione (MCP) which has been
shown to be a selective scavenger of the peroxynitrite
[55]. Other naturally occurring compounds containing
polyphenols include dark chocolate [56] and red wine [57].
Anthocyanins, rich in foods such as bilberry, are another
class of substances with antioxidant properties. In addition
to polyphenolic rings, anthocyanins possess a positively
Fig. 4 Short-term effect of
nifedipine. Mean defect of visu-
al field test (Octopus program
G1) at baseline and 60 min after
intake of 20 mg sustained-
release nifedipine in a)
improvement in patients with
digital vasospasm, and b) no
change in patients without digi-
tal vasospasm. When treatment
was continued for 12 months,
the improvement in the group
with vasospasm was still
detectable (not shown here)
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charged oxygen atom in their central ring which enables
them to readily scavenge electrons [58].
Ubiquinone, Coenzyme Q 10, is a coenzyme for the
inner mitochondrial enzyme complexes involved in energy
production within the cell with strong antioxidant proper-
ties. Coenzyme Q10 has been demonstrated to prevent lipid
peroxidation and DNA damage induced by oxidative stress
[59]. Ubiquinone has been studied well in dermatology but
unfortunately studies of its use in glaucoma are lacking and
therefore currently limit the use of this agent.
Melatonin (N-acetyl-5-methoxyryptamine) is an indole-
amine, secreted by the pineal gland, which exerts antiox-
idant properties. Melatonin has been shown to neutralise
free radicals [60]. In the retina, melatonin reduces the
elevation of cGMP by suppressing nitric oxide synthase
(NOS) activity and thereby levels of nitric oxide (NO)
indicating a neuroprotective role. In addition, melatonin
stimulates a number of antioxidative enzymes [61].
6. Inhibition of metalloproteinase 9 (MMP-9) reduces
retinal ganglion loss and tissue remodelling
MMP-2 and MMP-9 are upregulated in astrocytes of
glaucoma patients [62]. MMP-9 is also upregulated in the
circulating lymphocytes of glaucoma patients [63]. These
MMP’s, in particular MMP-9, are involved in both retinal
ganglion cell loss and in tissue remodelling. MMP-9 can be
inhibited pharmacologically by GM6001, also known as
Ilomastat (N-[(2R)-2-(hydroxamidocarbonylmethyl)-4-
methylpentanoyl]-L-tryptophan methylamide). Studies re-
veal that inhibition of MMP-9 with GM6001 prevents
retinal ganglion cell loss in an animal model [64].
Moreover, MMP-9 knock out mice do not show apoptosis
of retinal ganglion cells even when the optic nerve is
ligated [65]. MMP-9 most probably plays a role in the
pathogenesis of GON.
7. Stimulation of heat shock protein production (HSP)
protects proteins
Heat shock proteins (HSP’s) are produced by different
cells when subjected to stress (e.g. elevated temperatures
or oxidative stress). The upregulation of these proteins is a
protective mechanism as they act as molecular chaperones
protecting the three-dimentional structure of other pro-
teins. In a rat model, pharmacologically induced upregu-
lation of HSP’s, by the systemic administration of the
compound geranylgeranylacetone (GGA), protected retinal
ganglion cells from glaucomatous damage [66]. Whether
treatment with this drug or the natural stimulation of HSP’s
(eg. by sauna baths) is beneficial in humans, needs to be
studied.
Concluding remarks
Predictive medicine is expected to be most effective when
applied to multifactorial disease such as glaucoma. We
still do not know the exact mechanisms that lead to
damage of the trabecular meshwork and thereby to an
increase in IOP, nor do we know the exact mechanisms
leading to GON . Obviously there are a number of factors
and mechanisms involved. The different risk factors
Fig. 5 a Drainage of aqueous humor. Aqueous humor (green) drains
through the trabecular meshwork into Schlemm’s canal. b Trabecular
meshwork of a healthy individual. c Trabecular meshwork of a
glaucoma patient
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known, may finally lead to damage the same or similar
pathomechanisms to GON.
Therapeutically, we can either eliminate or mitigate risk
factors or target defined pathogenic steps. Risk factors that
can be influenced include increased IOP, low blood
pressure and vascular dysregulation. Blood pressure dips
can be avoided by intake of salt or fludrocortisone [22].
Vascular regulation can be improved locally by carbonic
anhydrase inhibitors [24], systemically with magnesium
[13, 15] or with low doses of calcium channel blockers
[67]. Oxidative stress at the level of mitochondria can be
reduced by the intake of gingko biloba [44, 45]. Whether
such treatment will be an adjunctive to the conventional
IOP-lowering treatment (e.g. in patients with POAG) or
whether it shall be used by itself (e.g. in patients with NTG)
remains to be seen.
Pathogenic steps that can be targeted include activation of
astrocytes, upregulation of NOS-2 or MMP’s. The very
different risk factors finally damage the optic nerve head in a
very similar fashion. At the moment any type of clinical or
experimental treatment is based on the prevention of GON.
A restoration of damaged function is at the moment not
possible at all. Already, many of these new treatment
strategies have proven to be beneficial in humans [68]. For
those remaining, further rigorous investigation is deserved
to open up a new therapeutic era in glaucoma.
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